Three-rate strict controls or subversion of the bottom price agency companies take the hot potato

The core of the draft drug price management measures is profit margin, during the period of cost rate and circulation ratio "three rate strictly controlled", the government's original intention is to eliminate the "asparagus film" high prices of drug breeding grounds, but when there are policies under the policy ——— "Gao Jin high out of high returns" of the new approach, so that domestic drug companies in the industry worry,　　In the future, reasonable and unreasonable costs are moved to the factory, which will increase the tax risk and potential violation risk of drug production enterprises. The unreasonable increase and transfer of the circulation link to the upstream "measures for the administration of drug prices" stipulates that the administration of drug prices has three forms of government pricing, government guided prices and market adjustment price, in addition to retail prices, the ex-factory price of drugs and the circulation of charges will become the object of government supervision. To this end, the "draft" for the detailed period of the cost rate, the circulation rate, sales profit margin, "three rate" to the price from the ex-factory prices to the retail link between the difference rate are detailed provisions. Its standard shows that the price of the factory (port) is divided into 0~5 yuan, 5~20 yuan, 20~100 yuan, 100~500 yuan, 500~1000 yuan, 1000~10000 yuan, more than 10000 yuan and other grades, the highest circulation rate (amount) corresponds to 40%, 30%+0.5　　, 25%+1.5, 20%+6.5, 15%+31.5, 8%+101.5, 901.5. "It is the government's intention to reduce the price of drugs by compressing the space for price increases, so as to eliminate the breeding grounds for sky-high drugs," he said. However, if the mechanism of drug-raising is still there, unreasonable increases and charges on the distribution channels will be moved to the head of the production enterprises, the enterprise's living space will not improve, but also may bear greater risk than the original.　　"A domestic Chinese medicine enterprises in charge of Willow (alias) told reporters. "Go ticket" increase counterfeit circulation risk "three rate strict controls" goal is through the compression circulation spreads, reduces the unnecessary proxy level, however the fact is the domestic agent also has the huge market demand. At present, 80% of production enterprises are using the investment agency, new drugs from the factory to the patient's hands, the general to go through the "pharmaceutical ——— the national General Agent ——— Regional Agents ——— Provincial agents ——— agents of the municipal ——— pharmaceutical representatives ——— Hospital Medicine Management Committee ——— Hospital Pharmacy ——— Doctors (departments) ——— patients"　　Nine links. Drug manufacturers will be 30 percent or even 20 percent of the market price of drugs to the agent, that is, the reserve prices agency, which includes a large number of intermediaries and a number of sales agencies. In the "Drug management measures" before the draft, because of the price and market price space, agents at the bottom to get the drugs, spare no effort to carry out government public relations and terminal promotion, including the high rebate to doctors, the final product admission and the Doctor prescription form to achieve sales. Surface "legitimate" agents, often derived from the "affiliated operation", some unlicensed operators or pharmaceutical representatives affiliated to the pharmaceutical enterprises, to carry out business activities, as long as pay to hangdepend on the enterprise certain tax, the anchored person can "the low enter high out" will the money wash out.　　However, this risk is very high, which provides a channel and convenience for the circulation of counterfeit drugs. Willow said, agent level drug "Go ticket" the whole process is already in the Open secret: the Pharmaceutical factory to 10 yuan/box of the bottom of the bag to the drug generation. First, the drug is anchored in a pharmaceutical enterprise A, through a spend 10 yuan of money from the manufacturers to buy medicine. Then a company to 30 yuan to invoice another pharmaceutical enterprise B,a company only earn the nominal price of the 5%~10% "ticket fee." Then B Company will be 70 yuan to the hospital invoice, B Company also earn the nominal price 5%~10% ticket fee.　　So from the pharmacy to the hospital between the 60 yuan difference. And throughout the process, only to go to the bill, the drug is actually from the pharmaceutical factory directly to the final delivery of drugs to the hospital pharmaceutical companies. Hospitals are paid to pharmaceutical companies in the form of cheques, and between pharmaceutical companies and pharmaceutical firms through cheques, but rebates to doctors are only in cash.　　The ticket took cash and provided a condition for the payment of the medical rebate. The reserve price of higher risk moved in the original floor agent mode, over the ticket, the money out in the entire benefit chain to redistribute, all by agents, layers of "go ticket" under, the birth of sky-high asparagus tablets.　　However, after the asparagus film incident, the government departments of the National Drug circulation launched a comprehensive investigation, in order to respond to the inspection, many domestic drug manufacturers quickly make adjustments, the reserve price has been changed to high prices.　　"Low into high out of high price" into "high into high out of high return", that is, in keeping the market price unchanged, commercial enterprises in order to obtain sufficient operating funds, the demand for production enterprises high invoicing, high rebate, high price, the circulation of money into a "clean", but the risk to the production enterprises. "Agents in the compression of the drug circulation rate, from the ex-factory price increase this road is not, but the drug companies still need these agents to sell drugs, in order not to lose drug orders, the agency's profit chain to change direction ——— from the enterprise high invoicing of the value of the Agency profits.　　"Willow said, now the production enterprises began to headache high billing, cash how to use a reasonable form to open to agents, in addition, because of high invoicing, the actual drug sales amount is not so much, involving the problem of empty tax, will be the biggest time bomb." Sound "Drug price management measures" can help reduce the price of medicine?　　Zhu Hengpeng, director of the Center for Public Policy Research at the Economic Institute of the Chinese Academy of Social Sciences, believes that the drug-raising mechanism and the monopoly of public hospitals in drug sales are the real reasons for high drug prices, and that it is impossible to solve the problem of high drug prices without reforming the system mechanism. Chinese Medicine (600056, share bar) vice President of Enterprise Management Association Sheng pointed out that the implementation of the "method" is almost impossible, and it is difficult to achieve the goal of reducing the price of drugs, but it is possible that the pharmaceutical industry, business and hospitals together to raise the price of medicine. Because in the case of market mechanism failure, strictly restricting the rate of obvious to the drug purchase and sale chain on the various links on the access toThe benefits of selling spreads are limited, and industrial, commercial and hospital survival can only distort and jointly raise the price of medicine.　　That is, "low into high out of high price to the Doctor high rebate" The price of the agent mode will become "high into high, high rebate, still give doctors a high rebate." Yang Changshun, general manager of Jiangxi San Jing Yi ' an Pharmaceutical Co., Ltd. said that under the new policy, the agent industry must change the original "ticket" mode of operation.　　For industrial enterprises, should adjust the agent model as soon as possible, can not simply make the upset price after the investment, in the investment at the same time, but also to give professional support, like the establishment of the team as a support agent system. Author: Wu Jingyan